Literature DB >> 12359626

Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.

David J Behm1, Christopher L Herold, Eliot H Ohlstein, Steven D Knight, Dashyant Dhanak, Stephen A Douglas.   

Abstract

1. Human urotensin-II (hU-II), a cyclic undecapeptide, is amongst the most potent mammalian vasoconstrictors identified, suggesting that hU-II and its G-protein-coupled receptor (UT) may regulate cardiovascular homeostasis. Such a hypothesis would benefit greatly from the development of selective UT antagonists. 2. Although the somatostatin (SST) antagonist SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide) is purported to block U-II-induced contractions in rat isolated aorta, little is known about its specific pharmacological properties. 3. SB-710411 (10 micro M) inhibited hU-II-induced contraction in rat isolated aorta causing a significant, parallel shift in the agonist concentration-response curve (pK(b) 6.28+/-0.11; n=8) with no suppression of the E(max). In contrast, SB-710411 did not alter the contractile actions of angiotensin-II, phenylephrine, or KCl. Paradoxically, however, SB-710411 potentiated the contractile response to endothelin-1 (pEC(50) 8.02+/-0.16 and 8.54+/-0.11, P<0.01; n=8). Rather than being specific toSB-710411, this phenomenon appears to be related to somatostatin receptor affinity and not intrinsic activity since the SST agonist somatostatin-14 and antagonist cyclo-somatostatin also potentiated endothelin-1-induced contraction. 4. SB-710411 (10 micro M) did not inhibit carbachol, sodium nitroprusside, IBMX, isoprenaline, and levcromakalim-induced reversal of tone established with noradrenaline. In contrast, however, SB-710411 significantly inhibited the reversal of tone established with endothelin-1 using the same vasorelaxants. 5. In summary, although SB-710411 inhibits the vasoconstrictor actions of hU-II in a competitive, surmountable manner, it also possesses additional pharmacological actions. Thus, whilst the present study is amongst the first to detail the properties of a functional U-II receptor antagonist, the data suggest caution be used when assessing data generated utilizing this moiety and other SST analogues.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359626      PMCID: PMC1573512          DOI: 10.1038/sj.bjp.0704887

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells.

Authors:  T Watanabe; R Pakala; T Katagiri; C R Benedict
Journal:  Circulation       Date:  2001-07-03       Impact factor: 29.690

2.  Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.

Authors:  Wojciech J Rossowski; Beng-L Cheng; John E Taylor; Rakesh Datta; David H Coy
Journal:  Eur J Pharmacol       Date:  2002-03-08       Impact factor: 4.432

3.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.

Authors:  R S Ames; H M Sarau; J K Chambers; R N Willette; N V Aiyar; A M Romanic; C S Louden; J J Foley; C F Sauermelch; R W Coatney; Z Ao; J Disa; S D Holmes; J M Stadel; J D Martin; W S Liu; G I Glover; S Wilson; D E McNulty; C E Ellis; N A Elshourbagy; U Shabon; J J Trill; D W Hay; E H Ohlstein; D J Bergsma; S A Douglas
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

4.  Urotensin II evokes potent vasoconstriction in humans in vivo.

Authors:  Felix Böhm; John Pernow
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

5.  Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II.

Authors:  J Paysant; A Rupin; S Simonet; J N Fabiani; T J Verbeuren
Journal:  Fundam Clin Pharmacol       Date:  2001-08       Impact factor: 2.748

6.  Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.

Authors:  Valeria Camarda; Anna Rizzi; Girolamo Calò; Gabrielle Gendron; Stephan I Perron; Evi Kostenis; Paolo Zamboni; Francesco Mascoli; Domenico Regoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-11-20       Impact factor: 3.000

7.  Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

8.  Effects of somatostatin and octreotide on portal-systemic collaterals in portal hypertensive rats.

Authors:  Hui-Chun Huang; Fa-Yauh Lee; Che-Chang Chan; Full-Young Chang; Sun-Sang Wang; Han-Chieh Lin; Ming-Chih Hou; Chien-Ting Chen; Chun-Ching Tai; I-Nien Lai; Shou-Dong Lee
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

9.  Somatostatin causes vasoconstriction, reduces blood flow and increases vascular permeability in the rat central nervous system.

Authors:  J B Long; D D Rigamonti; K Dosaka; J M Kraimer; A Martinez-Arizala
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

10.  Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein.

Authors:  S A Douglas; G R Beck; J D Elliott; E H Ohlstein
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

View more
  11 in total

Review 1.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

2.  Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation.

Authors:  D Chatenet; M Létourneau; Q T Nguyen; N D Doan; J Dupuis; A Fournier
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

3.  Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Authors:  Stephen A Douglas; David J Behm; Nambi V Aiyar; Diane Naselsky; Jyoti Disa; David P Brooks; Eliot H Ohlstein; John G Gleason; Henry M Sarau; James J Foley; Peter T Buckley; Dulcie B Schmidt; William E Wixted; Katherine Widdowson; Graham Riley; Jian Jin; Timothy F Gallagher; Stanley J Schmidt; Lance Ridgers; Lisa T Christmann; Richard M Keenan; Steven D Knight; Dashyant Dhanak
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

4.  The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.

Authors:  Christopher L Herold; David J Behm; Peter T Buckley; James J Foley; William E Wixted; Henry M Sarau; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

5.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

6.  Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.

Authors:  Riccardo Patacchini; Paolo Santicioli; Sandro Giuliani; Paolo Grieco; Ettore Novellino; Paolo Rovero; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2003-12       Impact factor: 8.739

7.  Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures.

Authors:  Francesco Merlino; Salvatore Di Maro; Ali Munaim Yousif; Michele Caraglia; Paolo Grieco
Journal:  J Amino Acids       Date:  2013-02-25

8.  Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons.

Authors:  Salvador Huitron-Resendiz; Morten P Kristensen; Manuel Sánchez-Alavez; Stewart D Clark; Stephen L Grupke; Christopher Tyler; Chisa Suzuki; Hans-Peter Nothacker; Olivier Civelli; Jose R Criado; Steven J Henriksen; Christopher S Leonard; Luis de Lecea
Journal:  J Neurosci       Date:  2005-06-08       Impact factor: 6.709

9.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

Review 10.  Therapeutic potential of blockade of the urotensin II system in systemic hypertension.

Authors:  Henry Krum; Will Kemp
Journal:  Curr Hypertens Rep       Date:  2007-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.